Interchangeability Is Inherent To Biosimilarity
Executive Summary
Interchangeability should be seen as a scientific concept rather than a therapeutic choice of biosimilar or reference biologic, Spanish physicians argue in a journal article.
You may also be interested in...
German Doctors Fear ‘Nocebo’ Impact From Substitution
Switching German patients from one biologic to another without involving their doctor could cause patients to perceive biosimilars as having inferior safety and efficacy, a local physicians’ body is warning.
France trials range of biosimilar incentives
French legislation setting out an ‘experiment’ to trial several different methods of incentivising biosimilar prescription in hospitals has been warmly welcomed by local generics and biosimilars association Gemme.
Clinical studies may soon be redundant
Advances in analytical techniques for biological drugs may soon render redundant large-scale Phase III clinical trials for biosimilar candidates, according to several speakers at the 16th Biosimilar Medicines Conference hosted by Medicines for Europe in London, UK. However, regulators showed some reluctance.